JAMA Int Med:阿片受体激动剂的维持疗法或可降低注射吸毒者感染丙肝的发生率

2014-10-30 佚名 生物谷

一项发表在国际杂志JAMA Internal Medicine上的研究报告中,来自波士顿大学医学院的研究人员通过研究表示,维持利用美沙酮或丁丙诺啡进行的阿片受体激动剂的治疗方法或许会降低年轻注射吸毒个体患丙肝的风险,其或许也是减少吸毒个体注射吸毒及传播丙肝的有效疗法。 利用注射毒品来吸毒是丙肝感染传播的主要途径,年轻的吸毒者是非常受关注的群体,因为其是引发丙肝感染传播的核心,对这些年轻吸毒者

一项发表在国际杂志JAMA Internal Medicine上的研究报告中,来自波士顿大学医学院的研究人员通过研究表示,维持利用美沙酮或丁丙诺啡进行的阿片受体激动剂的治疗方法或许会降低年轻注射吸毒个体患丙肝的风险,其或许也是减少吸毒个体注射吸毒及传播丙肝的有效疗法。

利用注射毒品来吸毒是丙肝感染传播的主要途径,年轻的吸毒者是非常受关注的群体,因为其是引发丙肝感染传播的核心,对这些年轻吸毒者进行干预显得非常关键。此前有研究表明,阿片受体激动剂的治疗可以有效减少丙肝感染的发生,但是研究者并不清楚为什么。

这项研究中,研究者Judith I. Tsui表示,从2000年1月至2013年8月我们对来自旧金山的552名年轻吸毒者进行了调查分析,其年龄中值为23岁,大部分的吸毒者都是无家可归的白人男性,这些个体药物(毒品)的平均使用时间为3.6年,而且33.3%的个体每天都会注射吸毒。大约60%的个体都会以海洛因作为注射毒品的选择,82.4%的个体在前一年中并没有使用任何药物进行治疗,而仅有4.2%的个体在前一年使用了阿片受体激动剂进行治疗。

在观察研究期间,研究者表示,在171个丙肝患者中每100个人年数中丙肝的发生率为25.1;人年数是一项生命计算单位,表示一个人一年的生命时间,用于医疗及人口统计。在过去三个月里利用阿片受体激动剂治疗的个体,相比那些没有进行治疗的个体来讲,前者丙肝的发生率较低。

最后研究者表示,年轻的注射吸毒者或许是美国及加拿大丙肝感染流行的主要原因,因此未来应该对这些人群进行大规模地干预;本文的研究结果也显示,阿片受体激动剂疗法可以有效降低吸毒个体丙肝的感染率及传播率,因此该疗法或许应该被考虑纳入到丙肝病毒感染的早期干预策略中去。

原始出处

Tsui JI1, Evans JL2, Lum PJ3, Hahn JA4, Page K5.Association of Opioid Agonist Therapy With Lower Incidence of Hepatitis C Virus Infection in Young Adult Injection Drug Users.JAMA Intern Med. 2014 Oct 27

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826265, encodeId=c34c182626505, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed May 06 08:52:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719722, encodeId=c1ed1e197229a, content=<a href='/topic/show?id=0a3a3941340' target=_blank style='color:#2F92EE;'>#吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39413, encryptionId=0a3a3941340, topicName=吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=112932803031, createdName=millore, createdTime=Wed May 06 08:52:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458380, encodeId=ee2e1458380f1, content=<a href='/topic/show?id=abec649e801' target=_blank style='color:#2F92EE;'>#注射吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64978, encryptionId=abec649e801, topicName=注射吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4066051585, createdName=cqlidoudou, createdTime=Sat Nov 01 00:52:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606314, encodeId=c785160631458, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 01 00:52:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627725, encodeId=24e3162e72599, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Nov 01 00:52:00 CST 2014, time=2014-11-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1826265, encodeId=c34c182626505, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed May 06 08:52:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719722, encodeId=c1ed1e197229a, content=<a href='/topic/show?id=0a3a3941340' target=_blank style='color:#2F92EE;'>#吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39413, encryptionId=0a3a3941340, topicName=吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=112932803031, createdName=millore, createdTime=Wed May 06 08:52:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458380, encodeId=ee2e1458380f1, content=<a href='/topic/show?id=abec649e801' target=_blank style='color:#2F92EE;'>#注射吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64978, encryptionId=abec649e801, topicName=注射吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4066051585, createdName=cqlidoudou, createdTime=Sat Nov 01 00:52:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606314, encodeId=c785160631458, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 01 00:52:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627725, encodeId=24e3162e72599, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Nov 01 00:52:00 CST 2014, time=2014-11-01, status=1, ipAttribution=)]
    2015-05-06 millore
  3. [GetPortalCommentsPageByObjectIdResponse(id=1826265, encodeId=c34c182626505, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed May 06 08:52:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719722, encodeId=c1ed1e197229a, content=<a href='/topic/show?id=0a3a3941340' target=_blank style='color:#2F92EE;'>#吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39413, encryptionId=0a3a3941340, topicName=吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=112932803031, createdName=millore, createdTime=Wed May 06 08:52:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458380, encodeId=ee2e1458380f1, content=<a href='/topic/show?id=abec649e801' target=_blank style='color:#2F92EE;'>#注射吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64978, encryptionId=abec649e801, topicName=注射吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4066051585, createdName=cqlidoudou, createdTime=Sat Nov 01 00:52:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606314, encodeId=c785160631458, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 01 00:52:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627725, encodeId=24e3162e72599, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Nov 01 00:52:00 CST 2014, time=2014-11-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1826265, encodeId=c34c182626505, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed May 06 08:52:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719722, encodeId=c1ed1e197229a, content=<a href='/topic/show?id=0a3a3941340' target=_blank style='color:#2F92EE;'>#吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39413, encryptionId=0a3a3941340, topicName=吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=112932803031, createdName=millore, createdTime=Wed May 06 08:52:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458380, encodeId=ee2e1458380f1, content=<a href='/topic/show?id=abec649e801' target=_blank style='color:#2F92EE;'>#注射吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64978, encryptionId=abec649e801, topicName=注射吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4066051585, createdName=cqlidoudou, createdTime=Sat Nov 01 00:52:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606314, encodeId=c785160631458, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 01 00:52:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627725, encodeId=24e3162e72599, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Nov 01 00:52:00 CST 2014, time=2014-11-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1826265, encodeId=c34c182626505, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed May 06 08:52:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719722, encodeId=c1ed1e197229a, content=<a href='/topic/show?id=0a3a3941340' target=_blank style='color:#2F92EE;'>#吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39413, encryptionId=0a3a3941340, topicName=吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=112932803031, createdName=millore, createdTime=Wed May 06 08:52:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458380, encodeId=ee2e1458380f1, content=<a href='/topic/show?id=abec649e801' target=_blank style='color:#2F92EE;'>#注射吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64978, encryptionId=abec649e801, topicName=注射吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4066051585, createdName=cqlidoudou, createdTime=Sat Nov 01 00:52:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606314, encodeId=c785160631458, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 01 00:52:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627725, encodeId=24e3162e72599, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Nov 01 00:52:00 CST 2014, time=2014-11-01, status=1, ipAttribution=)]

相关资讯

Nature:7篇NEJM研究展示丙肝治疗的重大胜利

最近一系列临床研究表明,我们已经可以制造出耐受良好的口服丙肝药物,这些药物能够有效消灭绝大多数感染者体内的丙肝病毒。本期Nature杂志特别刊登文章对丙肝治疗的过去、现在和未来进行了回顾和展望。人们首次认识到丙肝这种疾病是在上世纪七十年代,这是一种经血液传播的非甲非乙型肝炎病毒,是引起输血后肝炎的主要病因之一。1989年,人们首次鉴定到了丙肝病毒(HCV)。这种病毒善于躲避患者机体的免疫系统,

一张图解读丙肝现状

丙肝是一种由丙型肝炎病毒(HCV)感染引起的病毒性肝炎,能够形成病程几周的轻微肝脏疾病,严重的话则会导致肝癌。点击可放大上图由国际制药商协会联合会(InternationalFederation of Pharmaceutical Manufacturers &Associations)绘制而成,图中包含了丙肝是如何传播的,如何抑制丙肝,丙肝在全球的现状等信息。病毒性肝炎在世界各地都很流行

Lancet:丙肝新型抗病毒药物疗法安全有效

根据发表在《柳叶刀》(The Lancet)杂志上的两项研究的结果,两种新型的抗病毒药物疗法为大多数的丙型肝炎病毒感染者,甚至是最难于治疗的患者,提供了更短期、更有效且副作用更小的治疗选择。 两项研究均将焦点放在了1型丙型肝炎上。1型丙型肝炎是在美国、欧洲、亚洲北部、澳大利亚和南美洲等地区最常见且最难治愈的丙肝基因型。 全球有大约1.5亿人有慢性丙型肝炎病毒(HCV)感染,丙肝是导致肝硬化

Sovaldi对日本人丙肝实现100%治愈率(GS-US-337-0113研究)

丙型肝炎ledipasvir/sofosbuvir固定剂量复方片(LDV/SOF,90mg/400mg,每日一次),商品名Sovaldi,在丙肝领域实际重大突破,主要成果发表在新英格兰期刊上。相关资讯见:Nature:7篇NEJM研究展示丙肝治疗的重大胜利 ,NEJM:六项丙肝临床研究同时发表,EASL 2014:SOF/LDV固定剂量组合对难治性丙肝患者安全有效  最近一项在日本的研究

吉利德丙肝地位撼动——百时美丙肝新药Daklinza获欧盟批准——鸡尾酒治愈率达100%

丙肝治疗领域,吉利德可谓独领风骚,其明星药物Sovaldi(sofosbuvir)在今年上半年的销售额突破58亿美元,为其带来了滚滚财源。然而,这一格局即将打破。 近日,百时美施贵宝(BMS)丙肝新药Daklinza(daclatasvir)获欧盟批准,联合其他药物,用于所有1、2、3、4基因型慢性丙型肝炎(HCV)成人感染者的治疗。Daklinza是一种强效的泛基因型NS5A复制复合体抑制剂,

肝福音——吉利德丙肝鸡尾酒LDV/SOF年底在欧美上市

导读:吉利德(Gilead)是丙型肝炎领域的领军人物,到目前为止,其明星药物Sovaldi(sofosbuvir)的销售额已突破70亿美元,而该公司正在开发的新一代丙肝鸡尾酒疗法LDV/SOF,近日在欧盟方面也传来了好消息,欧盟CHMP已建议批准LDV/SOF。美国方面,FDA预计也将在今年晚些时候批准LDV/SOF,商品名为Harvoni,该药预计将很快在欧美2大市场上市。Harvoni又将成为